Hoth Therapeutics Files 8-K on Security Holder Votes

Ticker: HOTH · Form: 8-K · Filed: 2024-08-07T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

Related Tickers: HOTH

TL;DR

HOTH shareholders voted on something; details to follow.

AI Summary

Hoth Therapeutics, Inc. filed an 8-K on August 7, 2024, to report on matters submitted to a vote of security holders. The filing does not contain specific details about the vote or any associated resolutions, but it serves as a formal notification to the SEC regarding corporate governance actions.

Why It Matters

This filing indicates that Hoth Therapeutics held or is holding a vote of its shareholders, which is a key event in corporate governance and can signal important decisions being made by the company.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose new financial information or significant operational changes that would immediately impact risk.

Key Players & Entities

FAQ

What specific matters were submitted for a vote of security holders?

The filing does not specify the exact matters submitted for a vote, only that such matters were presented.

When did the vote of security holders take place?

The filing indicates the report date is August 7, 2024, suggesting the vote occurred on or around this date.

What is the company's principal executive office address?

The company's principal executive offices are located at 590 Madison Ave., 21st Floor, New York, New York 10022.

In which state was Hoth Therapeutics, Inc. incorporated?

Hoth Therapeutics, Inc. was incorporated in Nevada.

What is the SEC file number for Hoth Therapeutics, Inc.?

The SEC file number for Hoth Therapeutics, Inc. is 001-38803.

From the Filing

0001213900-24-066130.txt : 20240807 0001213900-24-066130.hdr.sgml : 20240807 20240807161518 ACCESSION NUMBER: 0001213900-24-066130 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240807 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20240807 DATE AS OF CHANGE: 20240807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 241183963 BUSINESS ADDRESS: STREET 1: 590 MADISON AVENUE STREET 2: 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646)756-2997 MAIL ADDRESS: STREET 1: 590 MADISON AVENUE STREET 2: 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 8-K 1 ea0210818-8k_hoththera.htm CURRENT REPORT false 0001711786 0001711786 2024-08-07 2024-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported) August 7, 2024   Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter)   Nevada   001-38803   82-1553794 (State or other jurisdiction of incorporation)   (Commission File Number)   (I. R. S. Employer Identification No.)   590 Madison Ave. , 21 st Floor New York , New York 10022 (Address of principal executive offices, including ZIP code)   ( 646 ) 756-2997 (Registrant’s telephone number, including area code)   Not Applicable (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   HOTH   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company  ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐             Item 5.07 Submission of Matters to a Vote of Security Holders.   On August 7, 2024,  Hoth Therapeutics, Inc. (the “Company”) held its 2024 annual meeting of shareholders (the “Annual Meeting”) for the purpose of holding a shareholder vote on Proposals 1, 2 and 3 set forth below. A total of 2,230,078 shares of the Company’s common stock constituting a quorum, were represented in person or by valid proxies at the Annual Meeting.   At the Annual Meeting, the Co

View on Read The Filing